Galecto Inc. Stock Price, News & Analysis

Galecto (NASDAQ:GLTO) announced two senior hires: Sherwin Sattarzadeh as Chief Operating Officer and Dr. Becker Hewes as Chief Medical Officer, effective January 5, 2026. The company said DMR-001, a potential best-in-class mutant calreticulin (mutCALR) monoclonal antibody, remains on track for an IND submission in mid-2026 with anticipated first-in-human subcutaneous dosing and Ph1 proof-of-concept data expected in 2027. Galecto reported a cash balance that includes a $285 million PIPE raised in November 2025 and said this funding provides runway into 2029 to support multiple data milestones. The company also disclosed inducement equity grants for both executives on January 5, 2026.

Galecto (Nasdaq: GLTO) announced an inducement equity grant approved by its board on December 15, 2025 and disclosed on December 16, 2025. The board granted non-qualified stock options to purchase 312,535 shares to one new employee under the company's 2022 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $32.00 per share and vest 25% on the first anniversary of the grant date, then an additional 1/48th each month thereafter, subject to continued employment.

Galecto (NASDAQ:GLTO) completed the acquisition of Damora Therapeutics and closed a concurrent Series C private placement raising approximately $284.9 million. The combined company says the financing provides runway into 2029 to advance Damora’s anti-mutCALR portfolio led by DMR-001, a monoclonal antibody with ~10-fold greater potency versus a reference molecule in preclinical Type 2 mutCALR models.

Key timelines: IND submission for DMR-001 expected mid-2026 and Phase 1 proof-of-concept data anticipated in 2027. Galecto also plans an IND for GB3226 in Q1 2026.

Galecto (NASDAQ: GLTO) reported third quarter 2025 operating and financial results on November 6, 2025. The company said it received constructive FDA pre-IND guidance for GB3226, a small-molecule dual ENL-YEATS/FLT3 inhibitor, and plans to submit an IND in Q1 2026 to start a Phase 1 AML trial evaluating safety, PK, preliminary efficacy and biomarkers with potential Phase 2 expansion.

Financials: $7.6M cash at Sept 30, 2025; R&D $1.4M (Q3 2025) vs $1.1M; G&A $1.7M vs $2.7M; net loss $3.1M or $(2.36)/share vs $3.9M prior-year quarter.

Galecto (NASDAQ: GLTO) will present preclinical data and clinical development plans for investigational candidate GB3226 at the 67th ASH Annual Meeting, Dec 6–9, 2025 in Orlando.

GB3226 is a first-in-class, orally bioavailable small molecule that dual-targets ENL-YEATS and FLT3, the latter mutated in ~30% of adult AML patients. Preclinical results reported include potent activity across diverse AML patient-derived samples, rapid tumor regression and prolonged survival in xenografts, favorable pharmacokinetics and tolerability in animals, and additive or synergistic effects with standard agents.

Galecto (NASDAQ: GLTO), a clinical-stage biotech company, reported Q2 2025 financial results and provided updates on its lead program. The company's primary focus is advancing GB3226, a dual ENL-YEATS and FLT3 inhibitor for AML treatment, with plans to submit an IND application to the FDA in Q1 2026.

Financial highlights include cash position of $10.2 million as of June 30, 2025, expected to fund operations into 2026. Q2 2025 saw a net loss of $3.4 million ($2.60 per share), improved from $5.3 million loss in Q2 2024. R&D expenses decreased to $1.5 million from $1.8 million, while G&A expenses reduced to $2.0 million from $2.8 million year-over-year.

Galecto (NASDAQ: GLTO) reported its Q1 2025 financial results and provided updates on its drug development programs. The company continues to advance GB3226, its dual ENL-YEATS and FLT3 inhibitor for acute myeloid leukemia (AML), with IND submission planned for Q1 2026. Preclinical data shows improved efficacy compared to existing treatments.

Financial highlights include:

• Cash position of $11.9 million as of March 31, 2025
• R&D expenses decreased to $0.7 million from $2.5 million year-over-year
• G&A expenses reduced to $1.9 million from $3.3 million year-over-year
• Net loss of $2.5 million ($1.92 per share) compared to $5.5 million ($5.05 per share) in Q1 2024

Galecto (NASDAQ: GLTO) has reported its full-year 2024 financial results and highlighted strategic developments. The company completed a strategic review focusing on oncology and liver diseases, acquiring global rights to GB3226, a dual ENL-YEATS and FLT3 inhibitor for AML treatment, with IND submission planned for Q1 2026.

Financial highlights include:

• Cash position of $14.2 million as of December 31, 2024
• R&D expenses decreased to $6.4 million from $23.8 million in 2023
• G&A expenses reduced to $10.5 million from $12.7 million in 2023
• Net loss of $21.4 million ($18.53 per share) compared to $38.3 million in 2023

The company continues its Phase 2 trial of GB1211 in combination with pembrolizumab for melanoma and head and neck cancer treatment. Current cash is expected to fund operations into 2026.

Galecto Inc (NASDAQ: GLTO), a clinical-stage biotechnology company developing treatments for cancer and severe liver diseases, has announced its participation in three major upcoming investor conferences.

The company will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, from 8:40-9:10 AM in a virtual format, featuring both a corporate presentation and one-on-one meetings. A live webcast will be available on Galecto's investor relations website, with replay access for 90 days.

Additionally, Galecto will attend the Leerink Partners Global Healthcare Conference on March 12 in Miami Beach, Florida, conducting one-on-one meetings, and the 37th Annual ROTH Conference on March 17-18 in Dana Point, CA, where they will deliver a corporate presentation and hold one-on-one meetings.